

# アルギニン残基修飾/除去によるMALDI-MS/MS解析における糖ペプチドのフラグメンテーションの改善

Improving Fragmentation of Arginine-Containing Glycopeptide Through Modifying or Removing Arginine Residue in MALDI Mass Spectrometry-Based Sequence Analysis

○谷口謙一・九山浩樹・梶原茂樹・田中耕一

株式会社島津製作所 田中最先端研究所

○Kenichi Taniguchi, Hiroki Kuyama, Shigeki Kajihara, Koichi Tanaka

Koichi Tanaka Laboratory of Advanced Science and Technology (KTLAST), Shimadzu Corporation

SHIMADZU

ms<sup>3</sup>d  
FIRST Program

## 1. INTRODUCTION

Glycosylation is one of the most abundant post-translational modifications, and more than 50% of human protein is estimated to be glycosylated. Profiling glycoprotein requires the structural characterization of both glycan and peptide moieties, and the clarification of glycan modification position. Arginine (Arg)-containing peptides exhibit a low degree of structurally informative fragmentation when investigated using the commonly used collision-induced dissociation (CID) analysis. This is also true with glycopeptides. Here we present an approach for enhancing the structurally informative fragmentation of Arg-containing glycopeptides<sup>[1]</sup>.

## 2. EXPERIMENTAL

### Material

High-purity MS grade 2,5-dihydroxybenzoic acid (DHB) was purchased from Shimadzu GLC (Tokyo, Japan). Human  $\alpha_1$ -acid glycoprotein, GluC and methylenediphosphonic acid (MDPNA) were purchased from Sigma (St. Louis, MO, USA). Sequencing-grade modified trypsin was obtained from Promega (Madison, WI, USA). Carboxypeptidase B was purchased from Worthington Biomedical Corp. (Lakewood, CO, USA). N-Succinimidyl 4-aza-6-(2,6-dimethyl-1-piperidinyl)-5-oxohexanoate (Tandem Mass Tag, (TMT)) was purchased from Thermo Fisher Scientific (San Jose, CA, USA). PAD4 (human recombinant) was purchased from Cayman Chemical Company (Lakewood, CO, USA).

### Glycopeptide Purification

The digest solutions derived from Trypsin or GluC digestion of  $\alpha_1$ -acid glycoprotein were subjected to size exclusion chromatography using a 2.1mm  $\times$  220mm Superdex Peptide column (GE Healthcare, Uppsala, Sweden) and a Nexera<sup>TM</sup> high-performance liquid chromatography (HPLC) system (Shimadzu, Japan), with 2mM NaHCO<sub>3</sub> as an eluent at a flow rate of 150  $\mu$ l/min. Fractions were collected for 5 to 7min. Under this condition, the N-linked glycopeptides were well separated from the non-glycosylated peptides.

### Glycopeptide Derivatization

Each dried glycopeptide fraction was dissolved in 19  $\mu$ l of 80% acetonitrile/water 0.4M 4-methylmorpholine. A volume of 1.5  $\mu$ l of 57mM N-succinimidyl 4-aza-6-(2,6-dimethyl-1-piperidinyl)-5-oxohexanoate (in acetonitrile) was then added to the solution. The mixture was incubated at room temperature for 30min, and 50  $\mu$ l of water was added to stop the reaction. After the evaporation, the amino group-derivatized glycopeptides were dissolved in 19  $\mu$ l of 100mM NaHCO<sub>3</sub> solution. Carboxypeptidase B solution (1  $\mu$ l, 5.7  $\mu$ M) was added, and the resulting solution was incubated at 37  $^{\circ}$ C for 2 h. For citrullination, the glycopeptides were dissolved in 20  $\mu$ l of 50mM Tris-HCl buffer (pH 7.4) containing 10mM CaCl<sub>2</sub> and 2 mM DTT. Five microliters of PAD4 was added to this solution and incubated at 37  $^{\circ}$ C for overnight.

### RP-HPLC Separation and Mass Spectrometry

The amino group-derivatized and Arg-removed glycopeptides were separated by RP chromatography on a Nexera<sup>TM</sup> system (Shimadzu, Japan). A C18 RP-HPLC column (Shim-Pack FC-ODS, 2.0mm  $\times$  150mm, Shimadzu, Japan) was used for the separation at a flow rate of 200  $\mu$ l/min with a linear gradient profile of 0 to 60% solvent B over 35min. Solvent A was water containing 0.1% (v/v) acetonitrile and 0.05% (v/v) TFA, and solvent B was 80% acetonitrile containing 0.05% (v/v) TFA. The fraction was spotted onto a DHB and MDPNA<sup>[2]</sup>-precoated u-focus MALDI target plate (700  $\mu$ m diameter) which was purchased from Hudson Surface Technology, Inc. (Old Tappan, NJ, USA). The mass spectra were acquired using an AXIMA Performance<sup>TM</sup> mass spectrometer and MS/MS spectra were obtained using an AXIMA Resonance<sup>TM</sup> UV-MALDI mass spectrometer (Shimadzu/Kratos, UK).

### Peak Processing

The peak lists for the database search were generated from MS spectra using Mass++ (version 2.3.0). The peaks in the MS spectrum were detected using the advanced peak-picking function MWD in Mass++. The neutral-loss peaks were then removed by the peak-filtering function that was originally developed in Mass++. Mass++ can be freely downloaded from the website <http://www.first-ms3d.jp/english/>.

### MS/MS Ion Search


MS/MS ion searches were performed by Mascot (version 2.4.0, Matrix Science, UK) on a local server with some customization. SwissProt (released January 11, 2011) was used as the database, and the taxonomy was set to Homo sapiens (human). Trypsin, Trypsin + Carboxypeptidase B-R (customized), or None was selected as the enzyme, with no potential cleavage. The mass tolerances of peptide and fragment ion were 0.3 Da. Fixed modifications were carboxamidomethylation of cysteine (+57 Da), citrullination of Arg (+1 Da, customized) and lysine TMT labeling (+224 Da). The variable modifications were HexNAc (+203 Da), N-terminal TMT labeling (+224 Da) and N-terminal glutamine deamination (-17 Da). MALDI-QIT-TOF was selected as the instrument type.

## References

- [1] K.Taniguchi, H.Kuyama, S.Kajihara, K.Tanaka, *J. Mass Spectrom.*, 2013, 48, 951–960.
- [2] H.Kuyama, K.Sonomura, O.Nishimura, *Rapid Commun. Mass Spectrom.*, 2008, 22, 1109–1116.

## 3. RESULTS and DISCUSSIONS

### Less informative fragmentation



### Solution




Fig.1 Deteriorated fragmentation of Arg-containing glycopeptide and its potential solution




Fig.2 Schematic depiction of enzymatic removal or modification of Arg residue.




Fig.3 LC-MALDI-MS spectrum of derivatized glycopeptides derived from trypsin digestion of human  $\alpha_1$  acid glycoprotein using Mass++.




Fig.4 Glycan sequencing of T4-1 and G5-1. The effect of Arg removal or modification and tertiary amine labeling on MS/MS fragmentation is presented. MS/MS spectrum of (a) intact T4-1, (b) labeled and Arg-removed T4-1, (c) intact G5-1 and (d) labeled and Arg-modified G5-1.




Fig.5 Peptide sequencing of T4-1 and G5-1. The effect of Arg removal or modification and tertiary amine labeling on MS<sup>3</sup> fragmentation is presented. MS<sup>3</sup> spectrum of (a) intact T4-1, (b) labeled and Arg-removed T4-1, (c) intact G5-1 and (d) labeled and Arg-modified T4-1. The score in parentheses indicates the value obtained after neutral-loss filtering of 203Da peaks.




Fig.6 Mascot score comparison of glycopeptides from trypsin or GluC digest of human  $\alpha_1$ -acid glycoprotein. The entries from T4-1 to G5-1 are Arg-containing glycopeptides; entries from T1-1 to T3 are glycopeptides containing lysine instead of Arg residue. The Mascot scores are the average of three experiments. Error bars represent standard deviation of the mean. Elevated levels were calculated as: "Score (TMT + Arg removal/modification + Filter (203)) - Score (No Label)" in Arg-containing glycopeptides and "Score (TMT + Filter (203)) - Score (No Label)" in lysine-containing glycopeptides.

## 4.CONCLUSIONS

Removal or modification of the Arg residue, tertiary amine labeling and neutral-loss filtering are useful for analyzing glycan structures, identifying glycoproteins and determining N-glycan binding positions.

## Acknowledgements

This research is supported by the Japan Society for the Promotion of Science (JSPS) through its "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)."